Cancer survival rates have improved dramatically over the past few decades thanks to ongoing advances in therapeutics. As research continues to push the boundaries of medicine, two innovative technologies stand out in the fight against cancer: Antibody-Drug Conjugates (ADCs) and PROteolysis TArgeting Chimeras (PROTACs). These cutting-edge approaches are refining how we treat cancer and opening…

Mapping the patient journey has become more complex, but also more critical to understand what is actually happening in the treatment or therapeutic landscape. This webinar will explore how leveraging PurpleLab’s integrated data sources, including claims and Social Determinants of Health (SDOH), can unlock critical insights for commercial, market access, and medical affairs teams.

Learn more about what PurpleLab can do for Clinical Trials Life Sciences Download

The Give Kids a Chance Act of 2025 is a piece of legislation poised to transform drug development for children with rare diseases and cancer. Reintroduced in the House of Representatives on February 12, 2025, by Congressman Michael McCaul, this bipartisan effort aims to extend the Priority Review Voucher (PRV) program beyond its anticipated September…

Mapping the patient journey has become more complex, but also more critical to understand what is actually happening in the treatment or therapeutic landscape. This webinar will explore how leveraging PurpleLab’s integrated data sources, including claims and Social Determinants of Health (SDOH), can unlock critical insights for commercial, market access, and medical affairs teams.

Alzheimer’s disease (AD) is a complex and heterogeneous condition requiring early detection and intervention. Biomarkers contribute to diagnostic processes and real-world evidence (RWE) outcomes. Robust real-world data can drive insights to bridge disease, policy, clinical trials, and access gaps in the diagnosis and treatment of AD, providing valuable objective endpoints.

Enhance clinical trial development with PurpleLab’s data-driven insights. ​ Access patient-level data, optimize trial design, improve recruitment, and generate real-world evidence.

Launching a new pharmaceutical product is a high-stakes endeavor, with nearly 40% of launches failing to meet expectations. To improve these odds, companies must shift to a data-driven approach, leveraging real-world insights to engage decision-makers effectively across the patient journey.

This case study explores how a pharmaceutical company successfully planned and executed a Phase III clinical trial for a new oncology drug.